Jan Eucker
- Hematology top 2%
- Multiple Myeloma Research and Treatments 14
- Genetics top 5%
- Chronic Lymphocytic Leukemia Research 8
- Myeloproliferative Neoplasms: Diagnosis and Treatment 5
- Oncology top 5%
- Cancer Treatment and Pharmacology 10
- Bone health and treatments 5
- Infectious Diseases top 5%
- Antifungal resistance and susceptibility 7
- Cancer Research top 10%
-
- Lymphoma Diagnosis and Treatment 6
-
- Fungal Infections and Studies 6
- Co-authors
- Orhan SezerKurt PossingerChristian JakobK. PossingerIvana ZavrskiKathrin NiemöllerUlrike HeiderChuanbing Zang
- Cited by
- HematologyGeneticsOncology
- Journals
- European Journal Of Haematology (7 papers)Annals of Hematology (6 papers)Anti-Cancer Drugs (5 papers)
- Partner nations
- GermanyUnited StatesChina
In The Last Decade
Jan Eucker
83 papers receiving 2.4k citations
Peers
Comparison fields: 5 of 117
- Hematology 628
- Genetics 332
- Oncology 760
- Infectious Diseases 378
- Cancer Research 284
Countries citing papers authored by Jan Eucker
This map shows the geographic impact of Jan Eucker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Eucker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Eucker more than expected).
Fields of papers citing papers by Jan Eucker
This network shows the impact of papers produced by Jan Eucker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Eucker. The network helps show where Jan Eucker may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Jan Eucker, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 4 | |
| 2 | 2023 | 32 | |
| 3 | TKI258, a multi-tyrosine kinase inhibitor is efficacious against human infant/childhood lymphoblastic leukemia in vitro. | 2014 | 4 |
| 4 | 2013 | 41 | |
| 5 | 2012 | 76 | |
| 6 | 2011 | 1 | |
| 7 | 2008 | 8 | |
| 8 | 2005 | 66 | |
| 9 | Serum levels of carboxy-terminal telopeptide of type-I collagen are elevated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lacking lytic bone lesions in conventional radiography. | 2003 | 26 |
| 10 | 2003 | 12 | |
| 11 | 2003 | 27 | |
| 12 | 2003 | 41 | |
| 13 | 2002 | 52 | |
| 14 | 2002 | 8 | |
| 15 | 2001 | 36 | |
| 16 | 2001 | 113 | |
| 17 | 2000 | 18 | |
| 18 | 2000 | 16 | |
| 19 | 2000 | 31 | |
| 20 | 1999 | 33 |
About Jan Eucker
Jan Eucker is a scholar working on Genetics, Hematology and Oncology, having authored 85 papers that have together received 2.5k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (14 papers), Cancer Treatment and Pharmacology (10 papers), Chronic Lymphocytic Leukemia Research (8 papers), Antifungal resistance and susceptibility (7 papers), Lymphoma Diagnosis and Treatment (6 papers), Fungal Infections and Studies (6 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers) and Bone health and treatments (5 papers). The work is most often cited by research in Hematology (628 citations), Genetics (332 citations) and Oncology (760 citations). Jan Eucker has collaborated with scholars based in Germany, United States and China. Frequent co-authors include Orhan Sezer, Kurt Possinger, Christian Jakob, K. Possinger, Ivana Zavrski, Kathrin Niemöller, Ulrike Heider, Chuanbing Zang, Barbara Graf and Klaus‐Dieter Wernecke. Their work appears in journals such as European Journal Of Haematology, Annals of Hematology, Anti-Cancer Drugs, Journal of Clinical Oncology and Mycoses.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.